ALN-AGT01 RVR for Mild to Moderate High Blood Pressure After Zilebesiran Treatment
Tests ALN-AGT01 RVR in adults with mild to moderate hypertension previously given zilebesiran.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
Key facts
- Where
- Lake Forest, Savannah, and Tampa, United StatesSee the 3 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07553442, who can take part
Where in United States
- Lake ForestLake Forest, United StatesTaking people
- SavannahSavannah, United StatesNo longer taking part
- TampaTampa, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Alnylam Pharmaceuticals
- Trial code
- NCT07553442
- Record updated
- 8 October 2026
- Original description
The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.Read full original descriptionShow less
A Phase 2, Randomized, Double-blind, Placebo-controlled, Single Dose Study of the Efficacy, Pharmacodynamics, and Safety of ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.
Part A: Inclusion Criteria; Is an adult participant with a mean seated office systolic blood pressure (SBP) of at least 130 mmHg and no more than than 170 mmHg; Either not taking antihypertensive medication or on stable therapy with up to 2 antihypertensive medications; Part B: Inclusion Criteria; Is an adult participant with a mean seated office SBP of at least 140 mmHg and no more than 170 mmHg; Has discontinued all prior antihypertensive medication other than a calcium channel blocker (CCB) and/or thiazide/thiazide-like diuretic (if taking) for at least 3 weeks; Both Parts: Exclusion Criteria; Has known secondary hypertension or serum potassium more than 5 mmol/L; Has an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73m\^2; Note: other protocol defined inclusion / exclusion criteria apply.